Greetings, advocates! Here’s a brief, interim hodgepodge of updates to keep you posted on government advocacy before the deluge of information swamps you in San Diego. The Next Big Thing: Part B Drug Reimbursements Medicare currently plans to adjust reimbursement of doctors in the MIPS program in 2019, not only based on E/M office services,…
Search results for: biosimilar
Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate…
Pfizer Files Suit Against J and J over Remicade Contracts
(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…
ARHP Stands Up for Members and Patients
Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. ARHP volunteers are actively involved in the ACR’s efforts to advocate for the care of our patients and the rheumatology professionals who…
RheumPAC: Answers to FAQs
What is RheumPAC? RheumPAC is the ACR’s nonpartisan political action committee (PAC) that works to elect and support pro-rheumatology candidates. It is the only PAC dedicated to the interests of the rheumatology profession. RheumPAC was created 10 years ago with the mission of educating, electing and supporting federal lawmakers who understand and can positively address…
FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
The FDA has approved adalimumab-adbm, a biosimilar, to treat multiple chronic inflammatory diseases…
N.Y. Rheumatologist Makes Advocacy a Priority
In 2005, not long after he became a private practice rheumatologist on Long Island, N.Y., Howard Blumstein, MD, dipped his toe into the advocacy pool at the encouragement of his partner, Max Hamburger, MD. “I thought it would be interesting to learn more about the issues that affect our patients and our practices, and I…
Investments in Legislative Advocacy Pay Off for Ohio Association of Rheumatology
Like many other state rheumatology associations, the Ohio Association of Rheumatology (OAR) has recently been actively advocating for patient care at the state legislative level. The most recent example of OAR’s efforts included an Advocacy Day on May 4, when members met with state legislators to discuss topics of interest. It was the fourth such…
Refocus Your Practice with Invigorating Sessions at 2017 ACR/ARHP Annual Meeting
The landscape of practice management and coding methodologies continues to be challenging in the current healthcare environment, and rheumatology practices must maintain focus on managing an effective and efficient practice. Join us at the 2017 ACR/ARHP Annual Meeting, Nov. 3–8 in San Diego, and gain knowledge and understanding of best practices in an ever-changing environment…
RISE Registry Data Now Available for Research Purposes
As medical professionals, we underÂstand the impact quality research can have on how we care for our patients. The extensive adoption of electronic health records (EHRs) has enabled the collection of big data in rheumatology. This has provided a new and unique opportunity for the rheumatology community to conduct in-depth research into how patients are…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 42
- Next Page »